Naloxone Saves Lives

California's Overdose Epidemic

California has faced a sharp rise in drug overdose deaths over the past decade, driven largely by opioids like fentanyl. In 2023 alone, the state recorded over 11,000 overdose fatalities, with opioids involved in the majority of cases.

This crisis is no longer confined to communities — it increasingly affects working-age adults across industries. Nearly every workplace faces the risk of unintentional exposure, and many employees struggle with substance use disorders, making overdose prevention and preparedness essential components of occupational safety

Naloxone, an opioid overdose reversal medication, is a proven lifesaving tool. It works by temporarily restoring normal breathing in individuals experiencing an opioid overdose. The FDA has approved two over-the-counter brands — NARCAN and RiVive — making this medication more accessible than ever. 

Having naloxone, both on the job and off the job, can mean the difference between life and death. Overdose life-threatening emergencies can happen anywhere, including job sites, offices and public-facing workplaces. In fact, Emergency Medical Services (EMS) was activated over 12,600 times to respond to potential opioid overdoses occurring in workplace settings in 2024. Employees may encounter overdoses among coworkers, contractors or visitors. For safety and health professionals, ensuring access to naloxone is not just a compliance measure – it’s an essential part of any first aid or emergency preparedness program.

California Naloxone and Workplace Legislation

Organizations operating in California will soon be required to supply naloxone. In September 2024, Gov. Gavin Newsom signed AB 1976, directing the California Division of Occupational Safety and Health to update regulations to include a workplace naloxone requirement and establish related enforcement practices.

Under this bill, the division must propose regulations by Dec. 1, 2027, requiring workplaces to include naloxone or another FDA-approved opioid antagonist in first aid kits, along with usage instructions and storage guidance. The Standards Board must review and consider adopting these changes by Dec. 1, 2028. The bill also clarifies liability protections for individuals who administer opioid antagonists in good faith during emergencies, including licensed emergency medical personnel, except in cases of gross negligence or misconduct.